Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04742023 · ClinicalTrials.gov registry record · Early Phase 1
Post-operative Complications and Graft Survival With Conventional Versus Continuous Glucose Monitoring in Patients With Diabetes Mellitus Undergoing Renal Transplantation
A Early Phase 1 study of Diabetes Mellitus, sponsored by Northwell Health.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT04742023 is a Early Phase 1 study of Diabetes Mellitus that has completed, run by Northwell Health. The registered enrollment target is 40 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04742023, a Early Phase 1 study of Diabetes Mellitus, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a prospective, randomized, single-blinded controlled trial in which the investigators evaluate post-operative serum glucose control using conventional point-of-care glucose monitoring in the morning and before meals (standard of care) versus continuous glucose monitoring using the Medtronic Guardian™ Sensor 3 continuous glucose monitor. The investigators will compare the average daily glucose level in the post-operative period (through post-operative day five) between the two arms in patients with diabetic nephropathy immediately post-renal transplant. This will serve as a pilot study to in order to power a main study.
Conditions Studied
Interventions
- DRUG Insulin
- DEVICE Continuous Glucose Monitor Application
- DIAGNOSTIC_TEST Finger Stick Glucose Measurement
- DEVICE Continuous Glucose Monitor Placebo Applied
Study Locations (1)
New York
- North Shore University Hospital - Manhasset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-04-21 |
| Est. Completion | 2023-12-21 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04742023
The ClinicalTrials.gov registry entry for NCT04742023 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (98% lower). The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 4 interventions - of which Insulin is the first listed.
NCT04742023 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04742023 about?
NCT04742023 is a clinical study titled "Post-operative Complications and Graft Survival With Conventional Versus Continuous Glucose Monitoring in Patients With Diabetes Mellitus Undergoing Renal Transplantation". This will be a prospective, randomized, single-blinded controlled trial in which the investigators evaluate post-operative serum glucose control using conventional point-of-care glucose monitoring in the morning and before meals (standard of care) versus continuous glucose monitoring using the Medtr...
What is the current status of trial NCT04742023?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2020-04-21. Estimated completion is 2023-12-21.
What conditions does trial NCT04742023 study?
This clinical trial studies the following conditions: Diabetes Mellitus.
What interventions are being tested in trial NCT04742023?
The interventions under investigation include: Insulin (DRUG), Continuous Glucose Monitor Application (DEVICE), Finger Stick Glucose Measurement (DIAGNOSTIC_TEST), Continuous Glucose Monitor Placebo Applied (DEVICE).
Who is sponsoring clinical trial NCT04742023?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04742023 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Genetic Studies of Insulin and Diabetes
RECRUITING
-
Improving Glycemic Control With Telemedicine and Smart Insulin Pens
RECRUITING · NA
-
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
RECRUITING
-
Genetics Of Autoimmunity In Type I Diabetes
RECRUITING
-
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
RECRUITING · NA
-
Therapeutic Plantar Electrical Stimulation Intervention During Hemodialysis to Improve Balance and Mobility
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.